Abstract: The development of targeted therapies for cancers with homologous recombination (HR) deficiencies has increasingly focused on exploiting synthetic lethality. DNA polymerase theta (Polθ), an enzyme critical for microhomology-mediated end joining (MMEJ), has emerged as a promising therapeutic target due to its overexpression in various cancers and its synthetic lethality with HR defects. ART899 is a novel, highly specific small-molecule inhibitor of the Polθ polymerase domain. Preclinical evaluations demonstrate that ART899 not only serves as a potent targeted agent but also acts as a highly effective, tumor-specific radiosensitizer. By impairing DNA double-strand break repair, ART899 significantly enhances the efficacy of fractionated radiotherapy in both in vitro and in vivo models, including under hypoxic conditions, without exacerbating toxicity in normal tissues. These findings support the clinical translation of ART899 for improving radiotherapy outcomes in solid tumors.
1. Introduction
Radiotherapy is a cornerstone of curative treatment for many solid tumors; however, intrinsic radioresistance and dose-limiting toxicities to surrounding normal tissues frequently compromise treatment efficacy. To overcome these challenges, researchers have sought to identify tumor-specific radiosensitizers. DNA polymerase theta (Polθ), encoded by the POLQ gene, is an ideal candidate for this approach. Polθ is a key mediator of microhomology-mediated end joining (MMEJ), an error-prone DNA double-strand break (DSB) repair pathway. While Polθ expression is minimal or absent in healthy tissues, it is frequently upregulated in multiple cancer types. Furthermore, Polθ deficiency is synthetically lethal in cancer cells harboring defects in homologous recombination (HR), such as those with BRCA mutations, making them highly reliant on MMEJ for survival. Building upon the discovery of early Polθ inhibitors like ART558, researchers have developed ART899, an optimized compound designed to provide safe and effective tumor radiosensitization and targeted therapy for HR-deficient and HR-proficient cancers alike [1].
2. Pharmacological Activity
ART899 demonstrates robust pharmacological activity both in vitro and in vivo. In cellular assays, ART899 effectively inhibits MMEJ activity with an IC50 of approximately 180 nmol/L. When combined with fractionated ionizing radiation (IR), ART899 profoundly radiosensitizes cancer cell lines, such as HCT116 (colorectal) and H460 (lung), reducing their survival by up to 4- to 5-fold compared to radiation alone. Crucially, this radiosensitizing effect is highly tumor-specific; ART899 does not enhance radiation toxicity in non-cancerous human fibroblasts (MRC5, AG01552) or normal epithelial cells (HIEC-6) [1].
In vivo pharmacokinetic profiling reveals that oral administration of ART899 achieves favorable plasma concentrations (≥1 mmol/L) sustained for several hours. In murine xenograft models bearing HCT116 tumors, the combination of oral ART899 (150 mg/kg twice daily) with fractionated radiation (10 x 2 Gy) resulted in a significant delay in tumor growth compared to radiation alone. Furthermore, the combination therapy was exceptionally well-tolerated, with no significant weight loss or treatment-related adverse events observed during the study or at necropsy [1].
3. Molecular Mechanism of Action
ART899 functions by specifically inhibiting the polymerase activity of Polθ, thereby disrupting the MMEJ repair pathway. Following exposure to ionizing radiation, Polθ inhibition prevents the efficient repair of DNA double-strand breaks. This impairment is evidenced by a marked increase in residual DNA damage markers, specifically γH2AX and 53BP1 foci, at 16 and 24 hours post-irradiation. The failure to repair these breaks leads to lethal chromosomal rearrangements, which manifest cellularly as an increased formation of micronuclei [1].
The mechanism of radiosensitization is also highly cell-cycle dependent. Because MMEJ is predominantly active during the S and G2 phases, Polθ inhibition is most lethal to actively replicating cells. Fractionated radiotherapy synergizes with this mechanism by allowing surviving cancer cells to progress into these vulnerable cell-cycle phases between radiation doses. Additionally, Polθ inhibition maintains its radiosensitizing efficacy even under severe hypoxic conditions (<0.1% oxygen), a microenvironmental factor that typically confers profound radioresistance in solid tumors [1].
4. Structure-Activity Relationship (SAR)
ART899 was developed to overcome the pharmacokinetic limitations of its predecessor, ART558, which suffered from poor metabolic stability in vivo. ART899 is a deuterated derivative of ART812 (a non-deuterated analog of ART558). The strategic incorporation of deuterium during the synthesis of ART899 significantly improved its metabolic profile. Microsomal stability assays demonstrated that ART899 possesses vastly superior metabolic stability, exhibiting drastically lower intrinsic clearance rates in both mouse and rat liver microsomes compared to ART558. Despite these structural modifications, ART899 retains high potency and specificity for the Polθ polymerase domain, maintaining an IC50 comparable to the original parent compound [1].
5. Current Limitations
While ART899 shows significant promise, a primary limitation in its clinical application relates to the tumor microenvironment. Although the compound is effective at radiosensitizing hypoxic cells in vitro, solid tumors in patients often feature regions of severe hypoxia characterized by highly limited vascular perfusion. A critical challenge remains in ensuring that systemically administered Polθ inhibitors like ART899 can achieve and maintain therapeutically effective concentrations within these poorly perfused, radioresistant tumor cores [1].
6. Future Perspectives
The successful preclinical validation of ART899 paves the way for broader clinical applications of Polθ inhibitors. The concept of targeting Polθ is currently being evaluated in a first-in-human Phase I clinical trial (NCT04991480) to assess safety and preliminary activity in patients with solid tumors. While initially conceptualized as a synthetic lethal therapy for HR-deficient cancers (e.g., BRCA-mutated tumors), the ability of ART899 to safely radiosensitize HR-proficient tumors expands its potential utility. Future research will likely focus on optimizing dosing schedules in combination with standard-of-care fractionated radiotherapy and investigating the efficacy of ART899 across a wider array of solid tumor malignancies [1].
